# Supira Medical

> Supira Medical is a clinical-stage cardiovascular device company in Los Gatos, California, building a next-generation percutaneous ventricular assist device (pVAD). Incubated inside Amr Salahieh's Shifamed innovation hub and led by CEO Nitin Salunke, the Supira System is a low-profile (10F), high-flow heart pump designed to give the heart temporary circulatory support during high-risk coronary interventions and cardiogenic shock, with the goal of moving more blood through a smaller sheath than the incumbent devices. The company raised a $120M oversubscribed Series E in March 2025 and won FDA approval to begin its SUPPORT II pivotal trial in 2026.

- **Founded:** 2018
- **Headquarters:** Los Gatos, California, United States
- **Founders:** Amr Salahieh (Founder of Shifamed / Chairman of the Board), Nitin Salunke (President & CEO)
- **Team size:** approximately 120 employees
- **Products:** Supira System (pVAD)
- **Notable:** Received FDA Breakthrough Device Designation for its pVAD, Closed a $120M oversubscribed Series E financing in March 2025 (roughly $250M raised to date), Completed enrollment of the SUPPORT I Early Feasibility Study (15 patients, four U.S. sites)

## Products & services

- **Supira System (pVAD)** — A next-generation percutaneous ventricular assist device with a 10F profile, novel impeller positioning, a flexible cannula for stability, and multiple onboard sensors delivering real-time pressure measurements. Designed to provide temporary, high continuous-flow mechanical circulatory support through a smaller introducer sheath than commercially available devices.

## Achievements

- Received FDA Breakthrough Device Designation for its pVAD
- Closed a $120M oversubscribed Series E financing in March 2025 (roughly $250M raised to date)
- Completed enrollment of the SUPPORT I Early Feasibility Study (15 patients, four U.S. sites)
- Received FDA approval to initiate the SUPPORT II Pivotal Trial (2026), the path toward a PMA submission
- Attracted sovereign-wealth and blue-chip life-sciences investors including Novo Holdings and QIA

## Latest updates

- **2026-04** — Announced FDA approval to initiate the SUPPORT II Pivotal Trial and advances in its cardiogenic shock program; appointed D. Keith Grossman to the Board of Directors.
- **2025-03** — Secured $120M oversubscribed Series E and completed enrollment of the SUPPORT I Early Feasibility Study in the U.S.

## Links

- Website: https://supiramedical.com
- LinkedIn: https://www.linkedin.com/company/supira-medical

---

Profile page: https://yespress.io/supira-medical
Published by YesPress — https://yespress.io
Last updated: 2026-07-10